John Lauriello, MD

John Lauriello, MD

Contact Dr. Lauriello

833 Chestnut Street
Suite 210
Philadelphia, PA 19107

(215) 955-6912
(215) 923-8219 fax

Most Recent Peer-reviewed Publications

  1. Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia
  2. Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia with Proton Magnetic Resonance Spectroscopy Brain Glutamate Level: A Mega-analysis of Individual Participant-Level Data
  3. Beyond 52-Week Long-Term Safety: Long-Term Outcomes of Aripiprazole Lauroxil for Patients With Schizophrenia Continuing in an Extension Study
  4. Using long-acting injectable antipsychotics to enhance the potential for recovery in schizophrenia
  5. Patient-Centered Psychopharmacology and Psychosocial Interventions: Treatment Selection and Shared Decision-Making to Enhance Chances for Recovery
  6. Prevalence and impact of relapse in patients with schizophrenia
  7. Drug-induced exanthema and resolution in treatment of Bipolar I Disorder with Lamotrigine and Aripiprazole
  8. Managing Transitions in Care and Adherence to Improve Outcomes in Schizophrenia
  9. Enhancing the treatment of patients with schizophrenia through continuous care
  10. Psychosis
  11. Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?
  12. Long-Acting Injectable Antipsychotics: Where Do They Fit in the Treatment Plan?
  13. Aripiprazole long-acting injectable for maintenance treatment of bipolar I disorder in adults
  14. Combination Antipsychotic Therapies: An Analysis from a Longitudinal Pragmatic Trial
  15. Misleading guidance from pharmacogenomic testing
  16. Multimodal Neuroimaging in Schizophrenia: Description and Dissemination
  17. Dr correll and colleagues reply
  18. Comparison of injectable and oral antipsychotics in relapse rates in a pragmatic 30-month schizophrenia relapse prevention study
  19. Update on New and Emerging Treatments for Schizophrenia
  20. Aripiprazole lauroxil long-acting injectable: The latest addition to second-generation long-acting agents
  21. The use of long-acting injectable antipsychotics in Schizophrenia: Evaluating the evidence
  22. Do long-term side effects matter? evaluating the risk of hip fracture in subjects with schizophrenia over a decade
  23. 21st century training in psychosis
  24. Does indication drive use, or does use drive indication?
  25. Comparison of SGA Oral Medications and a Long-Acting Injectable SGA: The PROACTIVE Study